Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Good Manufacturing Practices Formulation of a Kit for 155Terbium- and 225Actinium-Labeled Trastuzumab F(ab')2 and Translational Bridge Studies

EF 2025-26

Résumé
Certain breast and gastrointestinal cancers produce too much of a protein called HER2, causing tumours to grow faster and making treatment more difficult. Trastuzumab (Herceptin) attaches to HER2 and blocks its cancer-promoting signals, making it an effective treatment. However, resistance to Herceptin has become a challenge, highlighting the need for novel therapies. Dr. Reilly’s lab previously discovered that attaching a radioisotope, Actinium-225 (225Ac) to a portion of trastuzumab, called F(ab’)2, effectively treated HER2-positive breast cancer tumours in mice without harming healthy tissues. A novel chemical “linker,” called Crown, can attach 225Ac and Terbium-155 (155Tb), a radioisotope used for imaging, allowing clinicians to both see and treat the cancer, an approach known as “theranostics” (therapy + diagnostics). The next phase involves the development of a ready-to-use kit that enables efficient preparation of these targeted radiopharmaceuticals under strict safety and quality standards, called Good Manufacturing Practices (GMP). Therefore, the goals of this proposed research are to 1) formulate 155Tb- and 225Ac-trastuzumab F(ab')2 under GMP and confirm its safety, purity, and ability to bind HER2 and to 2) test how the drugs behave in the body, how long they stay there, how much radiation different organs absorb, and whether they cause any short-term toxicity. The formulation will be checked for sterility, stability, and quality for up to six months. Studies in mice will measure how the drugs spread and how much radiation organs receive. This research could lead to a new, personalized “see-and-treat” radiopharmaceutical for HER2-positive cancers, improving outcomes and helping launch future clinical trials in Canada.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
573090
Name
Pileggi Alessia M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Good Manufacturing Practices Formulation of a Kit for 155Terbium- and 225Actinium-Labeled Trastuzumab F(ab')2 and Translational Bridge Studies
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
155tb; 225ac; Alpha Particles; Good Manufacturing Practices (Gmp); Her2; Radioimmunotherapy; Radiopharmaceutical Kit; Radiotheranostics; Spect; Trastuzumab
Abstract
Certain breast and gastrointestinal cancers produce too much of a protein called HER2, causing tumours to grow faster and making treatment more difficult. Trastuzumab (Herceptin) attaches to HER2 and blocks its cancer-promoting signals, making it an effective treatment. However, resistance to Herceptin has become a challenge, highlighting the need for novel therapies. Dr. Reilly’s lab previously discovered that attaching a radioisotope, Actinium-225 (225Ac) to a portion of trastuzumab, called F(ab’)2, effectively treated HER2-positive breast cancer tumours in mice without harming healthy tissues. A novel chemical “linker,” called Crown, can attach 225Ac and Terbium-155 (155Tb), a radioisotope used for imaging, allowing clinicians to both see and treat the cancer, an approach known as “theranostics” (therapy + diagnostics). The next phase involves the development of a ready-to-use kit that enables efficient preparation of these targeted radiopharmaceuticals under strict safety and quality standards, called Good Manufacturing Practices (GMP). Therefore, the goals of this proposed research are to 1) formulate 155Tb- and 225Ac-trastuzumab F(ab')2 under GMP and confirm its safety, purity, and ability to bind HER2 and to 2) test how the drugs behave in the body, how long they stay there, how much radiation different organs absorb, and whether they cause any short-term toxicity. The formulation will be checked for sterility, stability, and quality for up to six months. Studies in mice will measure how the drugs spread and how much radiation organs receive. This research could lead to a new, personalized “see-and-treat” radiopharmaceutical for HER2-positive cancers, improving outcomes and helping launch future clinical trials in Canada.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pileggi, Alessia M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~